Physician profile
Robert J Ternes
NPI 1699703215
$3,862.07
in general payments reported to CMS, 2019-2025
30 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $390 · 2021: $867 · 2022: $542 · 2023: $565 · 2024: $510 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.81 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $475.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $354.35 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $263.20 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.88 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.06 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $238.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $224.66 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $173.79 | 2019-2022 | |
| Amgen INC. | $147.90 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $131.83 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $115.97 | 2020-2025 | |
| Daiichi Sankyo INC. | $99.95 | 2019-2021 | |
| Amarin Pharma, INC. | $94.20 | 2020-2021 | |
| Eisai INC. | $71.71 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $60.58 | 2019-2023 | |
| Biofire Diagnostics, LLC | $52.55 | 2020 | |
| Phathom Pharmaceuticals, INC. | $46.71 | 2024-2025 | Voquezna |
| Cequr Corporation | $32.88 | 2024-2025 | Cequr Simplicity |
| Radius Health, INC. | $29.28 | 2025 | |
| Allergan, INC. | $26.78 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.23 | 2019-2020 | |
| Exact Sciences Corporation | $23.20 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $21.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.81 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.22 | 2021 | |
| Boston Scientific Corporation | $17.87 | 2022 | |
| Genentech USA, INC. | $17.46 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ternes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.